Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.40 +0.40%

+$0.09 today

Market cap
$2.95B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 2.37M

Average 1.84M

DNLI Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Denali Therapeutics Inc.NASDAQ: DNLI

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 financing cash flow of $14.98M rose 823.2% year over year, behind the +1810.7% change in trailing-twelve-month financing cash flow. Sequentially, it fell 93.2% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +823.2% toward the trailing-twelve-month pace of +1810.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.98M-93.2% QoQ
Last fiscal yearDec 2025
$189.22M-60.9% YoY
LTMJun 2026
$425.38M+1810.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+823.2%——
1 year-60.9%——
3-year CAGR-15.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
189.22M USD
Year-over-year change
-60.9%
4-year CAGR
+76.8%

Financing Cash Flow vs competitors

How DNLI compares with its peers on the latest reported figures

  • DNLI's LTM Jun 2026 financing cash flow of $425.38M is the 3rd largest of the 11 companies compared; the peer median is $176.5M.
  • Its year-over-year change of +1810.7% is the highest of 11, against a peer median of +143.9%.
  • Financing cash flow amounts to 11803.1% of revenue for DNLI, versus a peer median of 68.6%.
DNLI Competitors Peer median
Financing Cash Flow for DNLI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$1.23B +505.2%+306.4%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$554.65M +115.5%-15.9%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$425.38M +1810.7%-15.2%11803.1%
BHVNBiohaven Ltd.LTM Jun 2026$371.73M -38.4%-17.0%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$271.31M +71.7%+89.7%1356.6%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$261.93M +546.0%—27.3%
PMNProMIS Neurosciences, Inc.LTM Jun 2026$91.07M +234.5%+33.9%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$87.96M +345.2%-12.7%—
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$60.4M -83.5%-45.3%1.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.04M +172.3%+87.5%—
ALECAlector, Inc.LTM Mar 2026$20.24M +94.0%+64.8%109.9%
Peer median (excluding DNLI) $176.5M+143.9%+33.9%68.6%

Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
Deferred Income Tax00000
Stock-Based Compensation85.25M99.85M108.1M102.88M99.63M
Change in Working Capital(20.41M)(24.03M)(289.93M)16.94M149K
Accounts Receivables00000
Inventory00000
Accounts Payables3.71M2.27M2.43M1.44M(7.52M)
Other Working Capital(24.12M)(26.3M)(292.36M)15.5M7.67M
Other Non-Cash Items5.76M(4.93M)(47.67M)(53.73M)(14.65M)
Operating Cash Flow(211.39M)(244.72M)(357.99M)(347.69M)(412.6M)
Capital Expenditures(8.5M)(17.83M)(12.94M)(15.91M)(9.5M)
Acquisitions (Net)0123.55M000
Purchases of Investments(1.42B)(1.12B)(1.81B)(1.23B)(441.26M)
Sales of Investments1.41B991.49M2.08B1.16B706.05M
Other Investing Activities0(123.55M)000
Investing Cash Flow(21.63M)(141.39M)249.31M(88.76M)255.28M
Debt Repayment000(32.34M)(8.17M)
Common Stock Issued19.35M296.22M17.82M499.25M197.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities014.46M017.39M0
Financing Cash Flow19.35M310.67M17.82M484.3M189.22M
Effect of Forex Changes00(75K)00
Net Change in Cash(213.67M)(75.43M)(90.94M)47.85M31.9M
Free Cash Flow(219.89M)(262.55M)(370.93M)(363.61M)(422.1M)

Denali Therapeutics Inc.

NASDAQ:DNLI

Intrinsic Alpha fair value

Locked

Current Price

$18.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.